The Landmark Series: Intraductal Papillary Mucinous Neoplasms of the Pancreas-From Prevalence to Early Cancer Detection

Modern series report a prevalence of pancreatic cysts in the general population of up to 50% in prospective studies. Of these, about half will be pancreatic cystic neoplasms (PCNs) that have varying degrees of malignant potential. Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are the most common PCNs and are known predecessors of pancreatic adenocarcinoma. Critically, they are one of the only radiographically identifiable precursors of pancreatic cancer and thus provide an opportunity for early cancer detection and surgical resection with curative intent. The combination of high prevalence and potential for malignant degeneration underscore the relevance of discussing the best management of IPMNs and improving the existing standard of care. Landmark data on IPMN prevalence, guidelines, surveillance, biomarkers, and immune landscape are highlighted.

Automated summary

Modern series have found that up to 50% of the general population may have pancreatic cysts, with about half of them being pancreatic cystic neoplasms (PCNs). The most common PCNs are intraductal papillary mucinous neoplasms (IPMNs), which are known as precursors of pancreatic adenocarcinoma. IPMNs are one of the few radiographically identifiable precursors of pancreatic cancer, providing an opportunity for early detection and surgical resection. This highlights the importance of discussing the best management of IPMNs and improving the existing standard of care, including prevalence, guidelines, surveillance, biomarkers, and immune landscape.